Elan seeks to resume drug trials

ELAN will make another attempt at developing a treatment for Alzheimer’s disease a year after a previous drug had to be cancelled.

Elan, which is still emerging from an accounting scandal last year, has filed an application with the US Food and Drug Administration (FDA) to begin trials of a new treatment for the disease.

Last January, Elan had to cancel patient trials of a previous treatment, AN-192, which was found to be causing inflammation of the central nervous system. According to brokers yesterday, the new treatment is a reformulation of AN-192.